Abstract
BackgroundWhen designing tumour vaccines, there are two primary types of antigens to consider: tumour-specific antigens (TSAs) and tumour-associated antigens (TAAs). TSAs, which derive from onco-viral antigens or gene mutation-driven neoantigens,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
